- Home
- ARRY vs ETNB Comparison
ARRY vs ETNB Comparison
Compare ARRY & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARRY
- ETNB
- Stock Information
- Founded
- ARRY 1989
- ETNB 2018
- Country
- ARRY United States
- ETNB United States
- Employees
- ARRY N/A
- ETNB N/A
- Industry
- ARRY Semiconductors
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- ARRY Technology
- ETNB Health Care
- Exchange
- ARRY Nasdaq
- ETNB Nasdaq
- Market Cap
- ARRY 1.3B
- ETNB 1.5B
- IPO Year
- ARRY 2020
- ETNB 2019
- Fundamental
- Price
- ARRY $8.97
- ETNB $8.87
- Analyst Decision
- ARRY Buy
- ETNB Strong Buy
- Analyst Count
- ARRY 17
- ETNB 10
- Target Price
- ARRY $9.03
- ETNB $27.22
- AVG Volume (30 Days)
- ARRY 9.2M
- ETNB 1.5M
- Earning Date
- ARRY 11-06-2025
- ETNB 11-06-2025
- Dividend Yield
- ARRY N/A
- ETNB N/A
- EPS Growth
- ARRY N/A
- ETNB N/A
- EPS
- ARRY N/A
- ETNB N/A
- Revenue
- ARRY $1,171,244,000.00
- ETNB N/A
- Revenue This Year
- ARRY $33.54
- ETNB N/A
- Revenue Next Year
- ARRY $13.00
- ETNB N/A
- P/E Ratio
- ARRY N/A
- ETNB N/A
- Revenue Growth
- ARRY 6.36
- ETNB N/A
- 52 Week Low
- ARRY $3.76
- ETNB $4.16
- 52 Week High
- ARRY $9.99
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- ARRY 60.62
- ETNB 43.45
- Support Level
- ARRY $8.55
- ETNB $8.46
- Resistance Level
- ARRY $9.43
- ETNB $9.47
- Average True Range (ATR)
- ARRY 0.58
- ETNB 0.46
- MACD
- ARRY 0.03
- ETNB -0.02
- Stochastic Oscillator
- ARRY 52.11
- ETNB 33.33
About ARRY Array Technologies Inc.
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers referred to as a single-axis tracker that move solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil and Rest of the World with the United States deriving the majority of the revenue.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).